Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Reduced prostasin (CAP1/PRSS8) activity eliminates HAI-1 and HAI-2 deficiency-associated developmental defects by preventing matriptase activation.

Szabo R, Uzzun Sales K, Kosa P, Shylo NA, Godiksen S, Hansen KK, Friis S, Gutkind JS, Vogel LK, Hummler E, Camerer E, Bugge TH.

PLoS Genet. 2012;8(8):e1002937. doi: 10.1371/journal.pgen.1002937. Epub 2012 Aug 30.

2.

The protease inhibitor HAI-2, but not HAI-1, regulates matriptase activation and shedding through prostasin.

Friis S, Sales KU, Schafer JM, Vogel LK, Kataoka H, Bugge TH.

J Biol Chem. 2014 Aug 8;289(32):22319-32. doi: 10.1074/jbc.M114.574400. Epub 2014 Jun 24.

3.

Delineation of proteolytic and non-proteolytic functions of the membrane-anchored serine protease prostasin.

Szabo R, Lantsman T, Peters DE, Bugge TH.

Development. 2016 Aug 1;143(15):2818-28. doi: 10.1242/dev.137968. Epub 2016 Jul 6.

4.

Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice.

Szabo R, Hobson JP, Christoph K, Kosa P, List K, Bugge TH.

Development. 2009 Aug;136(15):2653-63. doi: 10.1242/dev.038430.

5.

Loss of HAI-2 in mice with decreased prostasin activity leads to an early-onset intestinal failure resembling congenital tufting enteropathy.

Szabo R, Bugge TH.

PLoS One. 2018 Apr 4;13(4):e0194660. doi: 10.1371/journal.pone.0194660. eCollection 2018.

6.

Co-localization of the channel activating protease prostasin/(CAP1/PRSS8) with its candidate activator, matriptase.

List K, Hobson JP, Molinolo A, Bugge TH.

J Cell Physiol. 2007 Oct;213(1):237-45.

PMID:
17471493
7.

Regulation of feto-maternal barrier by matriptase- and PAR-2-mediated signaling is required for placental morphogenesis and mouse embryonic survival.

Szabo R, Peters DE, Kosa P, Camerer E, Bugge TH.

PLoS Genet. 2014 Jul 31;10(7):e1004470. doi: 10.1371/journal.pgen.1004470. eCollection 2014 Jul.

8.

Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development.

Szabo R, Molinolo A, List K, Bugge TH.

Oncogene. 2007 Mar 8;26(11):1546-56. Epub 2006 Sep 18.

PMID:
16983341
9.

Regulation of the matriptase-prostasin cell surface proteolytic cascade by hepatocyte growth factor activator inhibitor-1 during epidermal differentiation.

Chen YW, Wang JK, Chou FP, Chen CY, Rorke EA, Chen LM, Chai KX, Eckert RL, Johnson MD, Lin CY.

J Biol Chem. 2010 Oct 8;285(41):31755-62. doi: 10.1074/jbc.M110.150367. Epub 2010 Aug 9.

10.

Tissue distribution and subcellular localizations determine in vivo functional relationship among prostasin, matriptase, HAI-1, and HAI-2 in human skin.

Lee SP, Kao CY, Chang SC, Chiu YL, Chen YJ, Chen MG, Chang CC, Lin YW, Chiang CP, Wang JK, Lin CY, Johnson MD.

PLoS One. 2018 Feb 13;13(2):e0192632. doi: 10.1371/journal.pone.0192632. eCollection 2018. Erratum in: PLoS One. 2018 May 31;13(5):e0198569.

11.

Distinct Developmental Functions of Prostasin (CAP1/PRSS8) Zymogen and Activated Prostasin.

Friis S, Madsen DH, Bugge TH.

J Biol Chem. 2016 Feb 5;291(6):2577-82. doi: 10.1074/jbc.C115.706721. Epub 2015 Dec 30.

12.

Matriptase Complexes and Prostasin Complexes with HAI-1 and HAI-2 in Human Milk: Significant Proteolysis in Lactation.

Lai CH, Lai YJ, Chou FP, Chang HH, Tseng CC, Johnson MD, Wang JK, Lin CY.

PLoS One. 2016 Apr 4;11(4):e0152904. doi: 10.1371/journal.pone.0152904. eCollection 2016.

13.

Selective Inhibition of Prostasin in Human Enterocytes by the Integral Membrane Kunitz-Type Serine Protease Inhibitor HAI-2.

Shiao F, Liu LO, Huang N, Lai YJ, Barndt RJ, Tseng CC, Wang JK, Jia B, Johnson MD, Lin CY.

PLoS One. 2017 Jan 26;12(1):e0170944. doi: 10.1371/journal.pone.0170944. eCollection 2017.

14.

Prostasin and matriptase (ST14) in placenta from preeclamptic and healthy pregnant women.

Frederiksen-Møller B, Jørgensen JS, Hansen MR, Krigslund O, Vogel LK, Andersen LB, Jensen BL.

J Hypertens. 2016 Feb;34(2):298-306. doi: 10.1097/HJH.0000000000000795.

PMID:
26867056
15.

The matriptase-prostasin proteolytic cascade in epithelial development and pathology.

Miller GS, List K.

Cell Tissue Res. 2013 Feb;351(2):245-53. doi: 10.1007/s00441-012-1348-1. Epub 2012 Feb 18. Review.

PMID:
22350849
16.

Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation.

Netzel-Arnett S, Currie BM, Szabo R, Lin CY, Chen LM, Chai KX, Antalis TM, Bugge TH, List K.

J Biol Chem. 2006 Nov 3;281(44):32941-5. Epub 2006 Sep 15.

17.

Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis.

Buzza MS, Johnson TA, Conway GD, Martin EW, Mukhopadhyay S, Shea-Donohue T, Antalis TM.

J Biol Chem. 2017 Jun 30;292(26):10801-10812. doi: 10.1074/jbc.M116.771469. Epub 2017 May 10.

18.

Antithrombin regulates matriptase activity involved in plasmin generation, syndecan shedding, and HGF activation in keratinocytes.

Chen YW, Xu Z, Baksh AN, Wang JK, Chen CY, Swanson R, Olson ST, Kataoka H, Johnson MD, Lin CY.

PLoS One. 2013 May 13;8(5):e62826. doi: 10.1371/journal.pone.0062826. Print 2013.

19.

Defect of hepatocyte growth factor activator inhibitor type 1/serine protease inhibitor, Kunitz type 1 (Hai-1/Spint1) leads to ichthyosis-like condition and abnormal hair development in mice.

Nagaike K, Kawaguchi M, Takeda N, Fukushima T, Sawaguchi A, Kohama K, Setoyama M, Kataoka H.

Am J Pathol. 2008 Nov;173(5):1464-75. doi: 10.2353/ajpath.2008.071142. Epub 2008 Oct 2.

20.

Transport via the transcytotic pathway makes prostasin available as a substrate for matriptase.

Friis S, Godiksen S, Bornholdt J, Selzer-Plon J, Rasmussen HB, Bugge TH, Lin CY, Vogel LK.

J Biol Chem. 2011 Feb 18;286(7):5793-802. doi: 10.1074/jbc.M110.186874. Epub 2010 Dec 10.

Supplemental Content

Support Center